Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Recruiting

I'm Interested

Trial ID: NCT05063552

Purpose

This phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck cancer that has spread to other places in the body (metastatic or advanced stage) or has come back after prior treatment (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of cancer cells. This may help keep cancer cells from growing. Cisplatin and carboplatin are in a class of chemotherapy medications known as platinum-containing compounds. They work by killing, stopping, or slowing the growth of cancer cells. Docetaxel is in a class of chemotherapy medications called taxanes. It stops cancer cells from growing and dividing and may kill them. The addition of bevacizumab to standard chemotherapy or combination therapy with bevacizumab and atezolizumab may be better than standard chemotherapy plus cetuximab in treating patients with recurrent/metastatic head and neck cancers.

Official Title

A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers

Stanford Investigator(s)

Saad A. Khan, MD
Saad A. Khan, MD

Assistant Professor of Medicine (Oncology)

Eligibility


Inclusion Criteria:

   - Patient must have histologically confirmed squamous cell carcinoma of the head and
   neck (HNSCC) (excluding SCC of salivary glands, Epstein-Barr virus [EBV]-associated
   nasopharynx and skin)

   - Patient must have measurable disease as defined by Response Evaluation Criteria in
   Solid Tumors (RECIST) version (v)1.1. Measurements must be obtained within 4 weeks
   prior to randomization

   - Patient must be >= 18 years of age

   - Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1

   - Patient must have disease progression after prior therapy with an immune checkpoint
   inhibitor (ICI) in the first-line setting for recurrent/metastatic disease. Patient
   must have received first-line immune checkpoint inhibition for at least 6 weeks.
   Patients who have recurred or progressed within 12 weeks of immune checkpoint
   inhibition administered in the definitive setting for locally advanced disease (for
   e.g., in the context of a clinical trial) will also be eligible if local therapies are
   not feasible

   - Prior combination immunotherapies are permitted, but patient must not have had prior
   antiangiogenic treatment (e.g., bevacizumab, ziv-aflibercept, ramucirumab, sorafenib,
   sunitinib, pazopanib, regorafenib, lenvatinib, etc.). Patient must have completed any
   prior investigational therapy at least 28 days prior to randomization.

NOTE: Patients who received platinum/taxanes in the locally-advanced or
recurrent/metastatic setting and did not progress for at least 4 months thereafter, will be
eligible for this study. Patients who received cetuximab in the locally-advanced setting
and did not progress for at least 4 months thereafter, will also be eligible for this study

   - Patient must not have a history of >= grade 3 immune-related adverse event on prior
   ICI therapy (except those that could be managed with steroids [e.g., dermatologic
   toxicity, asymptomatic elevation of pancreatic enzymes, etc.]) and ICI could
   eventually be resumed. Patients who developed grade 3 endocrinopathies but are now
   stable on hormone supplementation and/or a daily prednisone dose of =< 10 mg (or
   equivalent doses of another glucocorticoid), will be permitted on this trial

   - Patient must not have a history of PD-1 inhibitor-induced hyper-progression, defined
   as 100% increase in tumor burden within 8 weeks (or 50% within 4 weeks) of initiating
   ICI and associated with clinical deterioration

   - Patient must not have any of the following criteria due to the possibility of
   increased risk for tumor bleeding with bevacizumab therapy:

      - Prior carotid bleeding,

      - Tumors that invade major vessels (e.g., the carotid) as shown unequivocally by
      imaging studies,

      - Central (e.g., within 2 cm from the hilum) lung metastases that are cavitary as
      shown unequivocally by imaging studies,

      - Any prior history of bleeding related to the current head and neck cancer,

      - History of gross hemoptysis (bright red blood of 1/2 teaspoon or more per episode
      of coughing) within 3 months prior to randomization

   - Patient must not have uncontrolled hypertension, a history of hypertensive crisis or
   hypertensive encephalopathy, or a history of grade 4 thromboembolism

   - Patient must not have a history of coagulopathy or hemorrhagic disorders

   - Patient must not have a history of thrombosis (e.g., pulmonary embolism or deep venous
   thrombosis) currently requiring therapeutic anticoagulation (prophylactic use of
   anticoagulation is allowed)

   - Patient must not be receiving chronic daily treatment with aspirin (> 325 mg/day) or
   non-steroidal anti-inflammatory agents (NSAID's) known to inhibit platelet function.
   The use of anti-platelet agents [e.g., dipyridamole (Persantine), ticlopidine
   (Ticlid), clopidogrel (Plavix)] is allowed only if patient is not receiving concurrent
   aspirin or NSAID's known to inhibit platelet function.

   - Patient must have PD-L1 expression >= 1% by combined positive score (CPS) in the tumor
   and/or immune cells

      - NOTE: Enrolling centers should test for PD-L1 CPS preferably using the SP263
      assay. Where this is not feasible, using their preferred Clinical Laboratory
      Improvement Act (CLIA)-certified or similar assay will be accepted. It is
      preferred for standard of care (SOC) PD-L1 assessments to be done on post-first
      line ICI samples if available, but SOC PD-L1 assessments on pre-ICI samples will
      be accepted for eligibility

   - Patient must not have a severe infection within 4 weeks prior to randomization,
   including, but not limited to, hospitalization for complications of infection,
   bacteremia, or severe pneumonia. Patients must not have active tuberculosis

   - Patient must not have a history of non-infectious pneumonitis requiring steroids at
   doses greater than or equal to 10 mg per day of prednisone or the equivalent on first
   line immunotherapy

   - Patient must not have a history of solid organ transplantation or stem-cell transplant

   - Patient must not be on immunosuppressive medication within 7 days prior to
   randomization except for: intranasal, inhaled, or topical steroids, local steroid
   injection, systemic corticosteroids at doses less than or equal to 10 mg per day of
   prednisone or the equivalent, or steroids used as premedication for hypersensitivity
   reactions

   - Patient must not have an active autoimmune disease that requires systemic treatment
   within 2 years prior to randomization. Patients who are receiving replacement therapy
   for adrenal or pituitary insufficiency will not be excluded

   - Patient must not have had a severe hypersensitivity reaction to any of the drug
   components used on this protocol or to chimeric or humanized antibodies or fusion
   proteins

   - Patient must not have received any live vaccine within 30 days prior to randomization
   and while participating in the study (and continue for 5 months after the last dose of
   atezolizumab on Arm C). Live vaccines include, but are not limited to, the following:
   measles, mumps, rubella, chicken pox, yellow fever, rabies, bacillus Calmette-Guerin
   (BCG), and typhoid (oral) vaccine. Patients are permitted to receive inactivated
   vaccines and any non-live vaccines including those for the seasonal influenza and
   coronavirus disease 2019 (COVID-19) (Note: intranasal influenza vaccines, such as
   Flu-Mist (registered trademark) are live attenuated vaccines and are not allowed). If
   possible, it is recommended to separate study drug administration from vaccine
   administration by about a week (primarily, in order to minimize an overlap of adverse
   events

   - Patient must not be pregnant or breast-feeding due to the potential harm to an unborn
   fetus and possible risk for adverse events in nursing infants with the treatment
   regimens being used.

      - All patients of childbearing potential must have a blood test or urine study
      within 14 days prior to randomization to rule out pregnancy.

      - A patient of childbearing potential is defined as anyone, regardless of sexual
      orientation or whether they have undergone tubal ligation, who meets the
      following criteria: 1) has achieved menarche at some point, 2) has not undergone
      a hysterectomy or bilateral oophorectomy; or 3) has not been naturally
      postmenopausal (amenorrhea following cancer therapy does not rule out
      childbearing potential) for at least 24 consecutive months (i.e., has had menses
      at any time in the preceding 24 consecutive months)

   - Patients must not expect to conceive or father children by using accepted and
   effective method(s) of contraception or by abstaining from sexual intercourse for the
   duration of their participation in the study and for 2 months after the last dose of
   treatment for patients assigned to Arm A and for 6 months after the last dose of
   protocol treatment for patients assigned to Arms B or C.

      - NOTE: Patients must also not breastfeed while on treatment and for 2 months after
      the last dose of treatment for patients assigned to Arm A and for 6 months after
      the last dose of treatment for patients assigned to Arms B or C

   - Patient must have the ability to understand and the willingness to sign a written
   informed consent document. Patients with impaired decision-making capacity (IDMC) who
   have a legally authorized representative (LAR) or caregiver and/or family member
   available will also be considered eligible

   - Leukocytes >= 3,000/mcL (must be obtained =< 14 days prior to protocol randomization)

   - Absolute neutrophil count (ANC) >= 1,500/mcL (must be obtained =< 14 days prior to
   protocol randomization)

   - Platelets >= 100,000/mcL (must be obtained =< 14 days prior to protocol randomization)

   - Hemoglobin (Hgb) > 9 g/dL (must be obtained =< 14 days prior to protocol
   randomization) (Note: Patient may be transfused to meet this criteria)

   - Total bilirubin =< 2.0 x institutional upper limit of normal (ULN) (=< 5.0 x
   institutional ULN if hepatic metastases present or =< 3 x ULN for patients with known
   Gilbert's disease) (must be obtained =< 14 days prior to protocol randomization)

   - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase
   [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
   =< 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic metastases present)
   (must be obtained =< 14 days prior to protocol randomization)

   - Alkaline phosphatase < 2.5 x institutional ULN (< 5.0 x institutional ULN if hepatic
   or bone metastases present) (must be obtained =< 14 days prior to protocol
   randomization)

   - Creatinine =< 1.5 x institutional ULN (must be obtained =< 14 days prior to protocol
   randomization)

   - Patients with uncontrolled or symptomatic hypercalcemia (ionized calcium > 1.5 mmol/L,
   calcium > 12 mg/dL or corrected serum calcium > ULN) must have their calcium levels
   corrected prior to randomization

   - Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral
   therapy with undetectable viral load within 6 months of randomization are eligible for
   this trial

   - For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral
   load must be undetectable on suppressive therapy, if indicated

   - Patients with a history of hepatitis C virus (HCV) infection must have been treated
   and cured. For patients with HCV infection who are currently on treatment, they are
   eligible if they have an undetectable HCV viral load

   - Patients with treated brain metastases are eligible if follow-up brain imaging after
   central nervous system (CNS)-directed therapy shows no evidence of progression.
   Patients must not have untreated brain metastases or leptomeningeal disease

   - Patients with a prior or concurrent malignancy whose natural history or treatment does
   not have the potential to interfere with the safety or efficacy assessment of the
   investigational regimen are eligible for this trial

   - Patients must not have uncontrolled pleural effusion, pericardial effusion, or ascites
   requiring recurrent drainage procedures (once monthly or more frequently). Patients
   may have indwelling catheters (e.g., PleurX [registered trademark])

   - Patient must not have significant cardiovascular disease (such as New York Heart
   Association class II or greater cardiac disease, myocardial infarction, or
   cerebrovascular accident) within 3 months prior to randomization, or unstable
   arrhythmia or unstable angina at the time of randomization

   - Patient must not receive any other chemotherapy, immunotherapy, antitumor hormonal
   therapy (excluding contraceptives and replacement steroids), radiation therapy, or
   experimental medications while on protocol treatment. Symptomatic lesions (e.g., bone
   metastases or metastases causing nerve impingement) amenable to palliative
   radiotherapy should be treated prior to randomization and patients must be recovered
   from the effects of radiation (there is no required minimum recovery period

   - Patient must not have had a surgical procedure (including open biopsy, surgical
   resection, wound revision, or any other major surgery involving entry into a body
   cavity) or significant traumatic injury within 28 days prior to randomization, or
   anticipation of need for major surgical procedure while on protocol treatment

   - Patient must not have any other disease, metabolic dysfunction, physical examination
   finding, or clinical laboratory finding that contraindicates the use of the agents
   used in this protocol, may affect the interpretation of the results, or may render the
   patient at high risk from treatment complications

   - Patient must not have a history of abdominal fistula, gastrointestinal (GI)
   perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to
   randomization

Intervention(s):

biological: Atezolizumab

biological: Bevacizumab

procedure: Biospecimen Collection

drug: Carboplatin

biological: Cetuximab

drug: Cisplatin

procedure: Computed Tomography

drug: Docetaxel

procedure: Echocardiography

procedure: Magnetic Resonance Imaging

procedure: Positron Emission Tomography

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Savanna Biedermann
sBiedermann@stanford.edu

New Trial Alerts

Receive email alerts when trials open to patients.